- Citations, last 5 years
- 67
- Works, last 5 years
- 6
- h-index
- 14
- Scientists listed
- 0
- Grants since 2016
- 3
Grants received
2018–2020 · research · R44
Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension
John Lee · PhaseBio Pharmaceuticals (United States) · funded by National Institutes of Health
2018–2020 · research · R44
Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension
John Lee · PhaseBio Pharmaceuticals (United States) · funded by National Institutes of Health
2018 · research · R44
Safety, tolerability and efficacy of a novel sustained release analog of vasoactive intestinal peptide, PB1046, in patients with pulmonary arterial hypertension
John Lee · PhaseBio Pharmaceuticals (United States) · funded by National Institutes of Health
